Healthcare Investors Hold Steady Amid Stock Declines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Fool
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 83.790
Low
102.00
Averages
111.76
High
120.00
Current: 83.790
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
Texas Instruments Reports Strong Quarterly Results and Upbeat Guidance
- Significant Revenue Growth: Texas Instruments reported first-quarter revenue of $4.83 billion, a 19% increase year-over-year, surpassing analyst expectations of $4.53 billion, highlighting the company's strong performance amid high demand for analog chips, which solidifies its market position.
- Stock Surge: The company's shares soared 18% on Thursday, marking its best single-day performance since 2000, with a year-to-date increase of approximately 60%, reflecting strong investor confidence in the company's future growth potential.
- Optimistic Outlook: Texas Instruments expects second-quarter revenue to range between $5 billion and $5.4 billion, representing a 17% growth at the midpoint, with earnings per share projected between $1.77 and $2.05, indicating a positive outlook on future market demand.
- Diverse Customer Base: With major clients like Apple, Nvidia, and Ford, along with a $60 billion investment to build three new plants in the U.S., Texas Instruments demonstrates its significance and ongoing growth potential in the global semiconductor market.
See More
AVIM Therapy Shows Significant Blood Pressure Reduction
- Immediate Blood Pressure Reduction: The MODERATO II trial demonstrated that AVIM Therapy activation resulted in an average reduction of 13.2 mmHg in office systolic blood pressure (oSBP), with 97% of patients achieving a reduction greater than 5 mmHg, highlighting its potential in hypertension management.
- Sustained Control Effects: At the 6-month follow-up, 89% of patients had an ambulatory systolic blood pressure (aSBP) below 140 mmHg, and 58% below 130 mmHg, indicating that AVIM Therapy effectively maintains blood pressure control in line with European and U.S. treatment goals.
- Long-Term Efficacy Validation: Sustained reductions in blood pressure were observed over 3.6 years in a sub-cohort of patients, further validating the long-term application value of AVIM Therapy, potentially offering new treatment options for high-risk patients.
- Strategic Collaboration Outlook: Orchestra BioMed's strategic collaboration with Medtronic is ongoing, with the BACKBEAT global pivotal trial set to evaluate the safety and efficacy of AVIM Therapy in uncontrolled hypertension patients, which is expected to create significant market opportunities for the company.
See More
Medtronic Acquires CathWorks, Redefining Cardiovascular Care
- Acquisition Scale: Medtronic's acquisition of CathWorks for $585 million not only solidifies its leadership in the cardiovascular sector but also enhances its product portfolio with the innovative FFRangio system, expected to boost the company's competitiveness in global markets.
- Technological Innovation: The CathWorks FFRangio system employs artificial intelligence and advanced computational science to provide non-invasive physiological assessments, significantly improving the accuracy and efficiency of cardiac disease diagnosis, which is anticipated to enhance patient treatment outcomes and reduce healthcare resource utilization.
- Clinical Trial Results: At the 2026 American College of Cardiology conference, CathWorks presented results from the ALL-RISE randomized control trial, demonstrating that the system is non-inferior to traditional methods in terms of major adverse cardiac events (MACE), further validating its clinical application effectiveness.
- Strategic Implications: This acquisition marks a significant advancement in Medtronic's digital transformation efforts, expected to expand global access to FFRangio technology, thereby enhancing physicians' diagnostic capabilities and providing higher quality medical services to patients.
See More
Healthcare Shareholders Await Recovery Amid Dividend Payouts
- Medical Device Market Performance: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a 35% drop in stock price over the past five years; its 3.3% dividend yield provides stable returns, alleviating shareholder concerns amid price volatility.
- Pharmaceutical Sales Challenges: Sanofi's Dupixent saw a 32.2% sales increase to €4.2 billion in 2025, yet faces patent expiration risks; the company anticipates a high-single-digit percentage sales growth in 2026, supported by a 5% dividend yield that offers ongoing shareholder returns.
- Growth Portfolio Potential: Bristol Myers Squibb's growth portfolio revenue rose from $22.6 billion to $26.4 billion in 2025, despite a 10% stock price decline over five years; its 4.2% dividend yield remains attractive to investors, particularly as legacy portfolio revenues decline.
- Market Outlook Uncertainty: Despite overall poor performance in healthcare stocks, investors remain optimistic about dividends from Medtronic, Sanofi, and Bristol Myers Squibb, as these companies enhance shareholder confidence through consistent dividend payments, reflecting the long-term investment value in the healthcare sector.
See More
Healthcare Investors Hold Steady Amid Stock Declines
- Medtronic Financials: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a more than 35% stock price drop over the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating a strong commitment to shareholders.
- Sanofi Drug Sales: Sanofi's Dupixent saw a 32.2% sales increase in 2025, generating €4.2 billion, and while facing patent expiration risks, total sales are expected to grow in the high single digits in 2026, with a dividend yield of 4.69%, providing stable returns for shareholders.
- Bristol Myers Growth Potential: Bristol Myers' growth portfolio revenue increased from $22.6 billion in 2024 to $26.4 billion in 2025, and although overall revenue is expected to slightly decline in 2026, the company maintains a 4.2% dividend yield, showcasing resilience and potential in the market.
- Investor Confidence: Despite challenges in healthcare stocks, all three companies offer attractive dividend yields, encouraging investors to hold their positions in a volatile market, reflecting the long-term investment value of the healthcare sector.
See More
Three Healthcare Stocks Offering Dividends Amidst Recovery Wait
- Medtronic's Financial Status: Medtronic reported $9 billion in revenue for Q3 2026, an 8.7% increase year-over-year, despite a stock price decline of over 35% in the past five years; the company has consistently raised its dividend for 48 years, currently yielding 3.3%, demonstrating its commitment to shareholders.
- Sanofi's Challenges: Sanofi's Dupixent drug saw a 32.2% sales increase in 2025, generating €4.2 billion, but faces patent expiration risks; the company expects total sales to rise by a high-single-digit percentage in 2026 while offering a 5% dividend yield to attract investors.
- Bristol Myers Squibb's Growth Potential: Although Bristol Myers Squibb's stock price has dropped about 10% over the past five years, its
See More
Texas Instruments Reports Strong Quarterly Results and Upbeat Guidance
- Significant Revenue Growth: Texas Instruments reported first-quarter revenue of $4.83 billion, a 19% increase year-over-year, surpassing analyst expectations of $4.53 billion, highlighting the company's strong performance amid high demand for analog chips, which solidifies its market position.
- Stock Surge: The company's shares soared 18% on Thursday, marking its best single-day performance since 2000, with a year-to-date increase of approximately 60%, reflecting strong investor confidence in the company's future growth potential.
- Optimistic Outlook: Texas Instruments expects second-quarter revenue to range between $5 billion and $5.4 billion, representing a 17% growth at the midpoint, with earnings per share projected between $1.77 and $2.05, indicating a positive outlook on future market demand.
- Diverse Customer Base: With major clients like Apple, Nvidia, and Ford, along with a $60 billion investment to build three new plants in the U.S., Texas Instruments demonstrates its significance and ongoing growth potential in the global semiconductor market.
See More
AVIM Therapy Shows Significant Blood Pressure Reduction
- Immediate Blood Pressure Reduction: The MODERATO II trial demonstrated that AVIM Therapy activation resulted in an average reduction of 13.2 mmHg in office systolic blood pressure (oSBP), with 97% of patients achieving a reduction greater than 5 mmHg, highlighting its potential in hypertension management.
- Sustained Control Effects: At the 6-month follow-up, 89% of patients had an ambulatory systolic blood pressure (aSBP) below 140 mmHg, and 58% below 130 mmHg, indicating that AVIM Therapy effectively maintains blood pressure control in line with European and U.S. treatment goals.
- Long-Term Efficacy Validation: Sustained reductions in blood pressure were observed over 3.6 years in a sub-cohort of patients, further validating the long-term application value of AVIM Therapy, potentially offering new treatment options for high-risk patients.
- Strategic Collaboration Outlook: Orchestra BioMed's strategic collaboration with Medtronic is ongoing, with the BACKBEAT global pivotal trial set to evaluate the safety and efficacy of AVIM Therapy in uncontrolled hypertension patients, which is expected to create significant market opportunities for the company.
See More
Medtronic Acquires CathWorks, Redefining Cardiovascular Care
- Acquisition Scale: Medtronic's acquisition of CathWorks for $585 million not only solidifies its leadership in the cardiovascular sector but also enhances its product portfolio with the innovative FFRangio system, expected to boost the company's competitiveness in global markets.
- Technological Innovation: The CathWorks FFRangio system employs artificial intelligence and advanced computational science to provide non-invasive physiological assessments, significantly improving the accuracy and efficiency of cardiac disease diagnosis, which is anticipated to enhance patient treatment outcomes and reduce healthcare resource utilization.
- Clinical Trial Results: At the 2026 American College of Cardiology conference, CathWorks presented results from the ALL-RISE randomized control trial, demonstrating that the system is non-inferior to traditional methods in terms of major adverse cardiac events (MACE), further validating its clinical application effectiveness.
- Strategic Implications: This acquisition marks a significant advancement in Medtronic's digital transformation efforts, expected to expand global access to FFRangio technology, thereby enhancing physicians' diagnostic capabilities and providing higher quality medical services to patients.
See More
